Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed solid tumor
• •* Locally advanced or metastatic disease
• •Refractory to standard therapy OR not amenable to standard therapy
• •No known CNS metastasis or CNS primary
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 70-100%
• •Life expectancy
• •At least 12 weeks
• •Hematopoietic
• •Neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •WBC count ≥ 3,500/mm\^3
• •Hemoglobin ≥ 9.5 g/dL
• •Haptoglobin ≥ 30 mg/dL
• •No concurrent hemolysis or history of non-drug-induced hemolysis (e.g., spherocytosis)
• •Hepatic
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Bilirubin ≤ 1.5 mg/dL
• •PT and PTT normal
• •Renal
• •Creatinine ≤ 1.5 mg/dL
• •Cardiovascular
• •No cardiac arrhythmias
• •No congestive heart failure
• •No myocardial infarction within the past 6 months
• •Other
• •Not pregnant
• •Negative pregnancy test
• •No nursing during and for at least 2 months after study participation
• •Fertile patients must use effective contraception during and for at least 2 months after study participation
• •HIV negative
• •No mental incapacity that would preclude giving informed consent
• •No moderate-to-severe high-frequency hearing loss
• •No persistent severe (grade 2) drug-induced peripheral neuropathy
• •No known allergy to cisplatin or any other platinum-containing compound
• •No serious or uncontrolled infection
• •No other medical condition or reason that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •At least 4 weeks since prior immunotherapy
• •Chemotherapy
• •Prior cisplatin allowed
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •At least 4 weeks since prior radiotherapy
• •Surgery
• •Not specified
• •Other
• •Recovered from all prior therapy
• •No concurrent vitamins, antioxidants, herbal preparations, or supplements
• •* Concurrent single tablet multivitamin allowed
• •No other concurrent investigational medications